study question: Is there an association between prolactin and markers of metabolic risk in polycystic ovary syndrome (PCOS)? summary answer: Low serum prolactin was a metabolic risk marker in PCOS. what is known already: Prolactin is routinely measured to exclude endocrine diseases in PCOS. Recent studies have suggested that prolactin can be used as a marker for metabolic and cardiovascular risk. study design, size, duration: Retrospective cross-sectional study in an academic tertiary-care medical center. Data were collected during 1997-2012. Premenopausal women (n ¼ 1007) with hirsutism and/or PCOS and 116 healthy, age-matched controls were included. Prolactin levels were measured in blood samples taken in the morning after a minimum of 2 h awakening time. Macroprolactinemia was excluded by the precipitation of serum with polyethylene glycol in patients with increased prolactin levels.
Introduction
Polycystic ovary syndrome (PCOS) is a prevalent endocrine condition, which is most often defined according to the Rotterdam criteria (2004) . The majority of patients with hirsutism are diagnosed with PCOS (Glintborg and Andersen, 2010) . PCOS is a diagnosis of exclusion, and prolactin levels are routinely measured in newly referred patients to exclude prolactinomas. PCOS is characterized by hyper-inflammation and insulin resistance and is associated with increased risk for diabetes and cardiovascular disease (Glintborg and Andersen, 2010; Wild et al., 2010) . It is recommended that patients with PCOS are screened for components in the metabolic syndrome including waist circumference, blood pressure, lipid status and blood glucose (Glintborg and Andersen, 2010; Wild et al., 2010) . In prospective studies, the most important predictive factor for the development of type 2 diabetes was obesity (Ehrmann et al., 1999; Norman et al., 2001) . Furthermore, the presence of hyperandrogenemia is associated with insulin resistance (Azziz et al., 2009; O'Reilly et al., 2014) . The optimal use of clinical and biochemical risk markers in patients with PCOS remains to be determined.
Prolactin is secreted not only from the pituitary gland but also from macrophages in the adipose tissue in response to inflammation and high glucose concentrations (Bouckenooghe et al., 2013) . In crosssectional studies, high prolactin was associated with an increased white blood cell count (Friedrich et al., 2010a) and autoimmune diseases (Cejkova et al., 2009) . It is therefore possible that prolactin can act as an adipokine. Insulin resistance was reported in patients with prolactinomas and insulin sensitivity increased during treatment with a dopamine agonist (Serri et al., 2006; dos Santos Silva et al., 2011; Auriemma et al., 2013; Ciresi et al., 2013) . Recently, bromocriptine was approved for the therapy of type 2 diabetes in the USA (Garber et al., 2013) . Data on prolactin, inflammation and insulin resistance are however inconsistent. Low prolactin levels predicted adverse metabolic outcomes in recent cross-sectional studies in healthy individuals (Balbach et al., 2013; Corona et al., 2014) and prolactin significantly increased following lifestyle intervention in obese children (Chirico et al., 2013) . These findings could suggest different associations between prolactin and metabolic risk factors when prolactin is within and outside the physiological range.
High prolactin may be a marker of low dopaminergic tonus in the central nervous system. Prolactin secretion is influenced by several hormonal parameters, age and smoking status. PCOS is associated with hyperandrogenemia and relatively high estrogen levels, which could stimulate prolactin secretion (Molitch, 2005) . On the other hand, depression and a decreased quality of life in PCOS could increase dopamine secretion and decrease prolactin levels (Hahn et al., 2005; Jones et al., 2008; Cinar et al., 2011; Altinok et al., 2014) .
The aim of the present study was to test the hypothesis that prolactin levels are a metabolic risk marker in PCOS.
Materials and Methods

Inclusion criteria
The study was designed as a retrospective observational study including premenopausal women referred to the outpatient clinic at the Department of Endocrinology, Odense University Hospital, during 1997 -2013 with hirsutism and/or PCOS. All patients had clinical/biochemical hyperandrogenemia and/or fulfilled a minimum of two of the Rotterdam criteria for PCOS.
Exclusion criteria
Women younger than 15 years were referred to the department of Pediatrics at Odense University Hospital and patients with a primary complaint of infertility were referred to the local fertility Clinic. Patients not attending for the measurement of hormonal or metabolic parameters were also excluded. Patients with serious endocrine diseases were excluded as previously described (Glintborg et al., 2004) . All included patients had normal thyroid function (thyroid stimulating hormone within reference range) and prolactin within reference intervals (normal range for prolactin 2 -23 mg/l).
Controls
Control data were available from three previous studies (Glintborg et al., 2005a (Glintborg et al., ,b, 2006 and have recently been published (Glintborg et al., 2012) . All controls had regular menses and did not suffer from hyperandrogenaemia or hirsutism. Forty-two women in the control group underwent adrenocorticotrophic hormone (ACTH) tests (Glintborg et al., 2005b) and 14 women (Glintborg et al., 2006) underwent an oral glucose tolerance test (OGTT). Due to the limited number of OGTT, data on area under the curve (AUC) insulin and 2 h glucose during the OGTT for the control group were not included.
Patients and controls paused oral contraceptive use for at least 3 months before evaluation. None were taking medicine known to affect hormonal or metabolic parameters.
Clinical, hormonal and metabolic analyses
Routine evaluation included a medical history, clinical examination and transvaginal ultrasound, and fasting blood samples were taken as previously described (Glintborg et al., 2004) . Menstrual cycle history was recorded in all patients using a standard scheme prepared for hirsute patients. Patients with regular periods and a cycle length 27 -35 days were classified as having regular menses. The remaining patients were classified as anovulatory. Hirsutism was assessed by the Ferriman -Gallwey score (FG-score) (Ferriman and Gallwey, 1961) . Waist circumference was measured to the nearest cm in a standing position midway between the lower costal margin and the iliac crest.
Fasting blood samples were drawn in the follicular phase (cycle days 2 -8) in patients with a cycle length shorter than 3 months; patients with cycle length .3 months had the blood samples drawn on a random cycle day. Blood tests included androgens (total testosterone, free-testosterone), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), 17-hydroxyprogesterone (17OHP), LH, FSH, prolactin and a lipid profile. Hemoglobin A1c measurements were performed routinely after 2003 . During 1997 -2002 , an OGTT was performed routinely (Glintborg et al., 2004) . Thereafter, an OGTT was performed in high-risk patients, as recommended by international guidelines (Salley et al., 2007) . Insulin, C-peptide and capillary blood glucose (CBG) were measured at baseline and at 30, 60 and 120 min after oral ingestion of 75 g glucose dissolved in water. The OGTT was performed in 406 patients.
ACTH tests were performed routinely during 1997-2002 (Glintborg et al., 2005b) . Thereafter, ACTH tests were only performed in patients with increased baseline 17OHP levels as previously discussed (Glintborg et al., 2005b) . The 0.25 mg ACTH test (Synacthen 0.25 mg/ml, Novartis Healthcare, Copenhagen, Denmark) was performed between 08.00 h and 10.00 h during the follicular phase (cycle days 2 -8). Cortisol and 17OHP were measured at baseline and at 30 and 60 min. ACTH tests were performed in 378 patients.
Assays
Prolactin levels were measured in blood samples taken in the morning after a minimum of 2 h awakening time using a solid phase two-site commercial kit (AutoDelfia, Perkin Elmer, Wallac Oy, Turku, Finland). The intra-assay variation was 2.2 -3.8% and the inter-assay variation was 23%. We excluded macroprolactinemia by the precipitation of serum with polyethylene glycol in patients with increased prolactin levels.
LH, FSH, cortisol and insulin were analyzed by time-resolved fluoroimmunoassay using commercial kits (AutoDelfia, Wallac Oy, Turku, Finland). Intra-assay variations were: FSH 1.0 -1.4%, LH 1.8 -9.4%, cortisol 2.7 -3.6% and insulin 2.1 -3.7%. Inter-assay variations were: FSH 2.1 -3.7%, LH 2.0-3.9%, cortisol 0.8 -1.9% and insulin 3.4 -4.0%.17OHP was analyzed by radioimmunoassay (RIA) using a commercial kit (Coat-A-Count, Diagnostic Products Corporation, Los Angeles, CA, USA). Intra-and inter-assay variations were 3.5-7.1 and 5.0-11%, respectively.
Serum total testosterone and SHBG were analyzed using a specific RIA after extraction as previously described (Lykkesfeldt et al., 1985) . In this method, testosterone, dihydrotestosterone and androstenedione are extracted before applying RIA and overestimation of testosterone levels is avoided. The method shows a close correlation with the determination of testosterone levels using mass spectrometry. The intra-assay coefficient of variation (CV) for total testosterone was 8.2% and for SHBG it was 5.2%. The inter-assay CV for total testosterone was 13.8% and for SHBG it was 7.5%. Free testosterone levels were calculated from measurements of total testosterone and SHBG. DHEAS was measured by RIA on diluted serum using specific antibodies (Lykkesfeldt et al., 1985) . The inter-assay variation for DHEAS was 10.7%.
Plasma total cholesterol, high-density lipoprotein (HDL), cholesterol and triglyceride (TG) were analyzed by enzymatic colorimetric reactions (Modular P, Roche), and low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation. Blood glucose was measured on capillary ear blood using Hemo Cue. We calculated homeostasis model assessment of insulin resistance (HOMA-IR) ¼ fasting insulin × fasting CBG/22.5 (Radziuk, 2000) , reference ≤15 pmol mmol l 22 .
Normal ranges for the individual hormones were for prolactin 2 -23 mg/l, LH 2-13 IU/l, FSH 2-7 IU/l, cortisol 200-700 nmol/l, insulin 18-173 pmol/l, total testosterone 0.55-1.8 nmol/l, free testosterone 0.006-0.034 nmol/l, SHBG 41-170 nmol/l, DHEAS 1200-9500 nmol/l and 17-OHP upper limit 12 nmol/l.
The lower limit of detection (lower limit for result given by laboratory) for the individual hormones was for prolactin 0.2 mg/l (1.0 mg/l), LH 0.1 IU/l (0.1 IU/l), FSH 0.1 IU/l (0.1 IU/l), cortisol 28 nmol/l (28 nmol/l), insulin 2 pmol/l (2 pmol/l), total testosterone 0.04 nmol/l (0.11 nmol/l), SHBG 0.5 nmol/l (1.0 nmol/l), DHEAS 50 nmol/l (150 nmol/l), 17-OHP 0.12 nmol/l (0.37 nmol/l).
Statistics
Parameters were not normally distributed and were therefore described using medians and quartiles. The Mann-Whitney test was used to compare differences between patients and controls, between the two patient groups according to prolactin below/above median and the presence of individual Rotterdam criteria (anovulation, polycystic ovaries, clinical/biochemical hyperandrogenism yes/no). The Chi-squared test was used to test for differences in frequencies between groups. Regression analyses were used to correct for differences in BMI between patients and controls. Patients were divided into two categories according to prolactin levels below/above the median level.
We performed multiple regression analyses to take into account that prolactin showed close association with age and smoking status. BMI was entered as an explanatory variable as well. In regression analyses, metabolic risk markers were entered as the dependent variable and prolactin, BMI, smoking status (yes/no) and age were entered as the explanatory variables. We used SPSS version 17 (SPSS, Chicago, IL, USA) in our calculations. P-values ,0.05 were considered significant.
Results
Patients versus controls
Hormonal and metabolic characteristics of patients and controls are presented in Table I . Prolactin levels were significantly lower in patients versus controls and remained significant after correcting for the higher BMI in the patient group. Table II shows the clinical and biochemical characteristics of included patients according to median prolactin level. Patients with prolactin levels above median had lower age, smoking prevalence, waist circumference, cholesterol, TG and LDL and higher FG-score, total testosterone, DHEAS, 17-hydroxyprogesterone, cortisol, and HDL compared with patients with prolactin levels below median. We found no significant differences between ACTH-stimulated 17OHP and cortisol between the two patient groups or between glucose and insulin responses during OGTT. In the subgroup of patients with BMI ≥25 kg/m 2 , patients with prolactin levels above median had lower age, smoking prevalence, cholesterol, TG and LDL and higher total testosterone, 17-OHP, cortisol, and HDL compared with patients with prolactin levels below median (data not shown).
Clinical, hormonal and metabolic characteristics in patients with PCOS/ hirsutism
Bivariate associations
Prolactin was inversely associated with age, smoking, waist circumference, total cholesterol, triglyceride, and LDL and positively associated with HDL, estradiol, total testosterone, DHEAS, 17-OHP, and cortisol (Table III) .
Multiple regression analyses
In multiple regression analysis, prolactin was inversely associated with LDL and positively associated with estradiol, 17-OHP and cortisol after correcting for age, BMI and smoking status (Table IV) .
Rotterdam criteria
Prolactin levels were higher in patients with biochemical hyperandrogenemia versus patients without biochemical hyperandrogenemia (P , 0.001), but were otherwise not associated with the presence of individual Rotterdam criteria (data not shown).
Discussion
To our knowledge this is the first study that evaluated the use of prolactin as a metabolic risk marker in a large well-described cohort of patients with PCOS and hirsutism. Prolactin levels were significantly lower in patients versus controls. In patients, prolactin levels were inversely associated with waist circumference, cholesterol and TG and positively associated with HDL. Furthermore, the significant inverse associations between prolactin and LDL were independent of smoking status, BMI and age. Our findings support an inverse association between prolactin levels and metabolic risk in patients with PCOS. Prolactin levels were inversely associated with smoking and age, whereas we found positive associations between prolactin and testosterone and estradiol. These data show that possible associations between prolactin and metabolic risk should take smoking and menopause status into account. The effect of smoking on prolactin levels was supported by our recent findings in PCOS (Glintborg et al., 2012) and studies in healthy women (Weisberg, 1985; Fuxe et al., 1989) . Nicotine activates the secretion of dopamine and therefore acts as a prolactin inhibitory factor (Kapoor and Jones, 2005) . Smoking was furthermore associated with a more adverse lipid profile in PCOS (Glintborg et al., 2012) . Our finding of low prolactin as a metabolic risk marker is supported by results from the Pomerania health study (Friedrich et al., 2010b) . Prolactin levels were inversely associated with waist circumference in 1857 healthy women aged 20-79 years, but possible interactions with smoking and menopause status were not investigated (Friedrich et al., 2010b) . Balbach et al. (2013) investigated a population-based cohort of 2027 women and reported an inverse association between prolactin and type 2 diabetes risk; however, this was not retained after correcting for age, BMI and smoking status. In young healthy subjects, prolactin was inversely associated with insulin sensitivity and glucose levels (Wagner et al., 2014) and low prolactin levels predicted the progression to metabolic syndrome (Chirico et al., 2013) and type 2 diabetes (Wang et al., 2013) . We found no significant associations between prolactin and HOMA-r or with AUC glucose or insulin. Included subjects were, however, relatively lean and only 20 patients in the study population were diagnosed with diabetes (Velling et al., 2011) . The inclusion of a relatively healthy and lean study population could have affected our findings.
The inverse associations between prolactin and metabolic risk reported in the present study contrast findings in patients with hyperprolactinemia (Serri et al., 2006; dos Santos Silva et al., 2011) . In these studies, patients with hyperprolactinemia were insulin resistant and dopamine agonists improved glucose metabolism and markers of insulin resistance along with decreasing BMI (Doknic et al., 2002; Serri et al., 2006; dos Santos Silva et al., 2011; Auriemma et al., 2013; Ciresi et al., 2013) . Hypogonadism is associated with insulin resistance and obesity . Hyperprolactinemia induces hypogonadism, which is reversed during treatment with dopamine agonists and could increase insulin sensitivity along with a decreased BMI.
Furthermore, the associations between prolactin and metabolic risk factors could differ for prolactin levels within and outside the physiological range. In agreement with this hypothesis, in vitro studies found that both low and high prolactin levels had adverse effects on pancreatic beta cell function (Auriemma et al., 2013; Wang et al., 2013) . Prolactin knockout and prolactin receptor deficiency was associated with reduced beta cell activity and glucose intolerance (Auffret et al., 2013) . In animal studies, prolactin injection was associated with weight loss and improved insulin sensitivity (Cincotta et al., 1989) . Physiologically elevated levels of prolactin could therefore be associated with increased beta cell mass and decreased metabolic risk as discussed by Wang (Wang et al., 2013) .
We found that prolactin levels were positively associated with estradiol and testosterone. This is in accordance with the stimulatory effect of sex hormones on pituitary prolactin secretion (Molitch, 2005) and the findings of lower prolactin levels in post-menopausal, compared with premenopausal, women (Roelfsema et al., 2012) . Furthermore, prolactin may directly stimulate gonadal androgen production (Dombrowicz et al., 1992) . Prolactin levels were positively associated with DHEAS, 17-OHP and cortisol, supporting a stimulatory effect of prolactin on adrenal activity. Obesity may stimulate cortisol secretion (Bjorntorp and Rosmond, 2000) , but significant associations between prolactin and cortisol and 17-OHP remained significant after correcting for BMI. In cell and animal studies, prolactin had direct stimulatory effects on adrenocortical cell proliferation and prolactin stimulation promoted increased weight of the adrenal glands (Jaroenporn et al., 2008) . More studies are needed to determine the role of prolactin on adrenal activity in PCOS.
Significantly lower prolactin levels in premenopausal patients with PCOS compared with age-matched controls could suggest increased dopaminergic tone in PCOS. Impaired quality of life and increased risk of depression could be associated with increased dopamine secretion and decreased prolactin levels in PCOS (Hahn et al., 2005; Jones et al., 2008; Cinar et al., 2011; Altinok et al., 2014) . In the present study, we found no significant associations between prolactin and LH, FSH or the presence of individual Rotterdam criteria. Patients were investigated during the follicular phase or during periods of amenorrhea after pausing oral contraceptive treatment for 3 months. Collection of blood samples during periods with low estrogen levels could be associated with the lower levels of prolactin in the present study. It was previously suggested that patients with PCOS had relative dopamine deficiency, which could lead to abnormal GnRH pulsatility, increased LH secretion, and a tendency to increased prolactin levels (Luciano et al., 1984) . The majority of studies could not confirm this hypothesis (Filho et al., 2007) and it is now generally recognized that patients with PCOS do not have increased prolactin levels.
Strengths and limitations may apply in the present study. A strength of the present study was the inclusion of a large and well characterized study population with different phenotypes of PCOS patients. limited by the fact that invasive investigations and echocardiography were not performed. The study design was cross-sectional and prospective studies are needed to further determine the impact of prolactin levels on cardiovascular outcomes. We standardized measurements of prolactin and excluded macroprolactinemia. Prolactin is however secreted in a pulsatile manner and several measures of prolactin may be needed to further investigate associations between prolactin and metabolic risk (Roelfsema et al., 2012) . Future studies should include post-menopausal women previously diagnosed with PCOS to further evaluate the importance of age and menopause status on prolactin secretion.
In conclusion, our findings suggest an inverse association between prolactin levels and metabolic risk. The positive association between prolactin and cortisol and 17-OHP needs further investigation.
